Endoscopic sclerotherapy: a risk factor for splanchnic venous thrombosis.
Endoscopic sclerotherapy has been widely advocated as primary therapy for patients surviving hemorrhage from esophageal varices. The potential for endoscopic sclerotherapy to limit subsequent surgical options remains unclear. The following study was undertaken to assess the endoscopic sclerotherapy-related incidence of splanchnic venous thrombosis in patients undergoing surgery for variceal bleeding. We retrospectively identified 27 patients who underwent portosystemic shunting after an episode of variceal hemorrhage documented by endoscopic examination. Eleven patients underwent endoscopic sclerotherapy before portosystemic surgery for shunting. Among the patients undergoing prior endoscopic sclerotherapy, 6/11 had partial splanchnic venous thrombosis at surgery compared with 2/16 in the non-endoscopic sclerotherapy group. This difference was statistically significant. Only one of the eight patients with splenic or portal vein thrombosis detected at surgery showed signs of the condition when an angiograph was performed. Endoscopic sclerotherapy appears to impose a significant risk for splanchnic venous thrombosis. This complication, not reliably detected by angiographic means, may limit the operative options and long-term outcomes of patients in whom endoscopic sclerotherapy fails.
Leach
S D
SD
Department of Surgery, Yale University School of Medicine, New Haven, CT 06510.
Meier
G H
GH
Gusberg
R J
RJ
D004724:Endoscopy; D004932:Esophageal and Gastric Varices / Q000628:therapy*; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011169:Portal Vein; D011170:Portasystemic Shunt, Surgical; D012189:Retrospective Studies; D012307:Risk Factors; D012597:Sclerosing Solutions / Q000009:adverse effects* / Q000627:therapeutic use; D013162:Splenic Vein; D013927:Thrombosis / Q000139:chemically induced*
D012597:Sclerosing Solutions